SCHEMBL1986941

SCHEMBL1986941

NC(CS)C(=O)[Fe](C(=O)C(N)CS)(C(=O)C(N)CS)C(=O)C(N)CS

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.55
SLC7A11 Q9UPY5 1/20 0.55
ENPEP Q07075 12/20 0.37
ANPEP P15144 4/20 0.36
MMP2 P08253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359384 1.00 PTGS1 (0.55) PTGS1SLC7A11ENPEPANPEPMMP2
Cysteine SCHEMBL663461 0.74
Cysteine SCHEMBL663459 0.74
SCHEMBL7878148 0.74
SCHEMBL7878149 0.74
Cysteine SCHEMBL7898895 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
Cysteine SCHEMBL1868335 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
Cysteine SCHEMBL339562 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
Cysteine SCHEMBL21110883 0.71 PTGS1 (1.00) PTGS1SLC7A11ENPEPANPEP
SCHEMBL8906558 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366738-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES INC (US) 2024-11-07 US disclosed
US-11992518-B2 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES, INC. (US) 2024-05-28 US disclosed
US-10968269-B1 MHC multimers in borrelia diagnostics and disease AGILENT TECHNOLOGIES, INC. (US) 2021-04-06 US disclosed
US-20210047383-A1 MHC Multimers in Borrelia Diagnostics and Disease DAKO DENMARK APS (DK) 2021-02-18 US disclosed
US-20200347103-A1 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS AGILENT TECHNOLOGIES INC (US) 2020-11-05 US disclosed
US-10611818-B2 MHC multimers in tuberculosis diagnostics, vaccine and therapeutics AGILENT TECHNOLOGIES, INC. (US) 2020-04-07 US disclosed
US-20190314471-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES, INC. 2019-10-17 US disclosed
US-10369204-B2 Molecular vaccines for infectious disease DAKO DENMARK A/S (DK) 2019-08-06 US disclosed
US-20120258126-A1 Molecular Vaccines for Infectious Disease DAKO DENMARK A/S (DK) 2012-10-11 US disclosed
US-20110318380-A1 MHC Multimers in Cancer Vaccines and Immune Monitoring DAKO DENMARK A/S (DK) 2011-12-29 US disclosed
US-20110236411-A1 MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics DAKO DENMARK A/S (DE) 2011-09-29 US disclosed
EP-2337795-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING Dako Denmark A/S (DK) 2011-06-29 EP disclosed
EP-2254592-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE Dako Denmark A/S (DK) 2010-12-01 EP disclosed
EP-2197908-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS Dako Denmark A/S (DK) 2010-06-23 EP disclosed
WO-2010037402-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037397-A1 MHC MULTIMERS IN CMV IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037395-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2009106073-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE DAKO DENMARK A/S (DK) 2009-09-03 WO disclosed
WO-2009039854-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS DAKO DENMARK A/S (DK) 2009-04-02 WO disclosed